Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents
DOI: https://doi.org/10.2147/JIR.S395137
IF: 4.5
2023-02-03
Journal of Inflammation Research
Abstract:Xin Zhao, 1 Chenhao Zhang, 2 Yi An, 3 Zixuan Zhang, 3 Jiahe Zhao, 3 Xinwen Zhang, 3 Yue Yang, 4 Wei Cao 4 1 Department of Rheumatology, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China; 2 Department of Emergency, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, 100102, People's Republic of China; 3 Department of School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China; 4 Department of Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, 100102, People's Republic of China Correspondence: Wei Cao, Department of Wangjing Hospital of China Academy of Chinese Medical Sciences, No. 6 Zhonghuan South Road, Chaoyang District, Beijing, 100102, People's Republic of China, Tel +86 10-84739099, Email Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by polyarticular, symmetric, and aggressive inflammation of the small joints in the hands and feet, resulting in dysfunction. With progress and development in medicine, treatment of RA is constantly evolving, making several drugs available for the treatment of RA. From the nonsteroidal anti-inflammatory drugs (NSAIDs) at the start of illness to glucocorticoids and then to conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), therapeutic-use drugs for RA have been keeping pace with scientific research. However, various types of drugs have additional side effects when used over the long-term. New and emerging biological and targeted agents have been widely applied in recent years; however, the side effects have not been thoroughly investigated. In this paper, we review the research progress on liver damage caused by novel biological and targeted agents available for RA treatment. The aim is to provide a reference for rational clinical administration of such drugs. Keywords: liver damage, novel biological agents, research progress, rheumatoid arthritis, targeted agents The etiology and pathogenesis of rheumatoid arthritis (RA) are unknown, but environmental factors, gene factors as well as environmental-genetic interaction are considered as major etiology of RA.Environmental factors especially cigarette smoking increase the risk of developing RA in those who have a hereditary disposition. 1 And the prevailing pathogenic model of RA assumes an autoimmune mechanism. 2 And the disease causes cartilage and bone destruction, resulting in degradation of joint functions, and even joint deformity and disability, seriously impairing the quality of life of patients. 3 In recent years, novel biological and targeted agents have been increasingly used in the clinical treatment of RA, and compared to traditional anti-rheumatic drugs, significantly improve the clinical symptoms and slow down disease progression in patients. In the 2021 American College of Rheumatology (ACR) guidelines for the Treatment of Rheumatoid Arthritis, an adjustment was made with respect to bDMARDs and tsDMARDs as second-line therapy, especially tsDMARDs, which have a significantly improved therapeutic status compared to the previous guidelines, and reflected their efficacy and safety. 4 Currently, there are a relatively large number of novel biological agents clinically used for RA, including tumor necrosis factor inhibitors (TNFi), interleukin (IL) receptor antagonists, B-cell depleting agents, T-cell targeting drugs, etc. Targeted DMARDs mainly include Janus kinase (JAKs) inhibitors. They belong to different drug categories and have different pathophysiological targets and mechanisms of action (refer to Figure 1 and Table 1). Table 1 Currently Approved Biological DMARDs and Targeted Agents Figure 1 Biological and targeted agents in the treatment of rheumatoid arthritis. Antigen-presenting cells deliver their own antigens via major histocompatibility complexes to T cells, releasing lymphokines and activating macrophages to provide assistance to B cells. The latter may be induced to produce autoantibodies such as anti-citrullinated proteins. Autoantibodies are bound to the respective autoantigens and form immune complexes in the synovial membrane. These immune complexes bind to macrophages and other cells via Fc receptors and complement receptors, activating the secretion of pro-inflammatory cytokines and other inflammatory mediators like tumor necrosis factor, interleukins and macrophages via lymphokines, such as T-cell interferon or IL-17. RA rarely affects the liver by itself but liver damage has been a common adverse effect in RA patients over long-term or on irregular medica -Abstract Truncated-
immunology